Cargando…

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma

Detalles Bibliográficos
Autores principales:	Moran, Angela M., Ramakrishnan, Sanjay, Borg, Catherine A., Connolly, Clare M., Couillard, Simon, Mwasuku, Christine M., Pavord, Ian D., Hinks, Timothy S. C., Lehtimӓki, Lauri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605198/ https://www.ncbi.nlm.nih.gov/pubmed/32584603 http://dx.doi.org/10.1164/rccm.202003-0729LE

Ejemplares similares

Reply to Lipworth et al.: Don’t Forget about Facilitatory Effects of Corticosteroids on β(2)-Adrenoceptors in Acute Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
por: Couillard, Simon, et al.
Publicado: (2022)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
por: Isoyama, Shoko, et al.
Publicado: (2022)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma
por: Goyack, Laura, et al.
Publicado: (2023)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)

Eosinophilic bronchiolitis successfully treated with benralizumab
por: Sugino, Keishi, et al.
Publicado: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020)

Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab
por: Masaki, Katsunori, et al.
Publicado: (2021)

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection
por: Takano, Tomotsugu, et al.
Publicado: (2021)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

Case Report: Eosinophilic Bronchiolitis With Eosinophil ETosis in Mucus Plugs Successfully Treated With Benralizumab
por: Sasaki, Hisashi, et al.
Publicado: (2022)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
por: BLOMBERG, Maria, et al.
Publicado: (2020)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
por: Hassani, Marwan, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
por: Pavord, Ian D., et al.
Publicado: (2021)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
por: Nanzer, Alexandra M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g29u5prnn09hhn0dnakcop8i9h